Use
Antihemophilic factor VIII (recombinant), Recombinate,Kogenate, Bioclate, Helixate, is a plasma protein that functionsin the normal blood-clotting cascade by increasing theVmax for the activation of clotting factor X by factor IXa inthe presence of calcium ions and negatively charged phospholipids.Factor VIII is used in the treatment of hemophiliaA.Recombinant factor VIII is indicated for the treatment ofclassical hemophilia (hemophilia A) and for the preventionand treatment of hemorrhagic episodes and perioperativemanagement of patients with hemophilia A. The drug is alsoindicated for the treatment of hemophilia A in persons whopossess inhibitors to factor VIII.Recombinant factor VIII is supplied in sterile, singledosevials. The product is stabilized with human albuminand lyophilized. The product must be stored at 2°C to 8°C,without freezing. In some instances, the powder may bestored at room temperature for up to 3 months without lossof biological activity. Shaking of the reconstituted productshould be avoided because of the presence of the albumin.The drug must be administered by IV bolus or drip infusionwithin 3 hours of reconstitution.